Accessibility Menu
BridgeBio Oncology Therapeutics logo

BridgeBio Oncology Therapeutics(NASDAQ) BBOT

Market Cap$719.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-12%
5 YearN/A
1 Year-11%
1 Month+0%
$8.91
-0.78%
-0.07Today
BridgeBio Oncology Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 8.982026-09-04
BridgeBio Oncology Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.75%USD 8.742026-08-28
1 month+0.22%USD 8.962026-08-05
3 month+14.98%USD 7.812026-06-05
Year to date-28.27%USD 12.522025-12-31
1 year-10.91%USD 10.082025-09-04
Since inception-11.87%USD 10.192024-02-09

BridgeBio Oncology Therapeutics Financials at a Glance

Market Cap

$719.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$182.11M

EPS (TTM)

-$1,232.83

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

2.01 (High)

Price

$8.91

Volume

14,088.209

Open

$8.88

Previous Close

$8.98

Daily Range

$8.78 - $9.05

52-Week Range

$7.00 - $14.87

Estimated Earnings Date

Nov 11, 2026

BBOT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics, Inc. makes medicines for hard-to-treat cancers. It fixes genetic mistakes that help tumors grow. These new drugs aim to be safer for patients.

The Pipeline for Tumors

  • BBO-8520: Direct inhibitor targeting specific KRAS G12C mutations in patients with non-small cell lung cancer.
  • BBO-11818: Pan-KRAS inhibitor designed to treat various advanced solid tumors and pancreatic cancer.
  • BBO-10203: Novel therapy blocking signals between RAS and PI3Kα in breast, colorectal, and lung cancers.

Building the War Chest

  • Merged with Helix Acquisition Corp. II on Aug. 11, 2025, to become a publicly traded company.
  • Secured approximately $260.9 million through a private placement financing completed in August 2025.
  • Partnered with Lawrence Livermore National Security to use high-performance computing for drug discovery.
  • Entered licensing agreements with Leidos Biomedical Research for several oncology-focused drug candidates.

Why the Tech Wins

The company uses advanced computational modeling and specialized licensing to target cancer-driving proteins once considered untreatable. By focusing on both the active and inactive states of these proteins, it aims to create more durable treatments for patients.

Counting the Costs

  • Net loss was $56.5 million for the three months ended June 30, 2026, up 99% year over year.
  • Research and development expenses reached $89.0 million for the six months ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities totaled $344.1 million as of June 30, 2026.
  • General and administrative costs rose 313% to $11.0 million in the three months ended June 30, 2026.
  • Market capitalization was $610.0 million in the second quarter of 2026, up 144.3% year over year.

Evolution Summary

BridgeBio Oncology Therapeutics transitioned from a private subsidiary to a well-funded public developer of precision cancer drugs. Its growth is driven by deep technical partnerships and a pipeline focused on specific genetic mutations.

AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

92

CEO

Pedro J. Beltran, PhD

Website

www.bbotx.com

Headquarters

South San Francisco, CA 94080, US

BBOT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-46.90%

Return on Capital

-35.23%

Return on Assets

-48.34%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$719.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

80.17M

Volume

14.09K

Avg. Volume

372.83K

Financials (TTM)

Gross Profit

-$186.00K

Operating Income

-$198.96M

EBITDA

-$194.66M

Operating Cash Flow

-$193.14M

Capital Expenditure

-$677.00K

Free Cash Flow

-$193.82M

Cash & ST Invst.

$225.71M

Total Debt

$2.51M

BridgeBio Oncology Therapeutics Performance Analysis

BridgeBio Oncology Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
BridgeBio Oncology Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
BridgeBio Oncology Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00-90.5%
20232023-12-31USD -0.00900.0%
20242024-12-31USD -5,756.41287820560.0%
20252025-12-31USD -4.30-99.9%
BridgeBio Oncology Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-57.0%
Q42025-12-3134.2%
Q12026-03-31-8.0%
Q22026-06-30-52137.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$719.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.18M

N/A

Employees

88

N/A

Net Income

-$56.45M

-98.5%

EBITDA

-$56.45M

-88.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$225.71M

+71.8%

Total Debt

$2.51M

-11.3%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.96M

-22.0%

Short Term Debt

$554.00K

+73.1%

Return on Assets

-48.34%

N/A

Return on Invested Capital

-61.20%

N/A

Free Cash Flow

-$44.41M

-88.8%

Operating Cash Flow

-$44.36M

-90.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCSOculis Holding AG
$12.17-0.41%
PHATPhathom Pharmaceuticals, Inc.
$9.23-2.84%
SEPNSepterna Inc
$37.42+1.82%
ANABAnaptysBio, Inc.
$57.18+0.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$103.37+0.08%
BNCCea Industries
$4.96+0.42%
NVDANvidia
$227.02-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.78+0.07%

Questions About BBOT

What is the current price of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics is trading at $8.93 per share.

What is the 52-week range for BridgeBio Oncology Therapeutics?

Over the past 52 weeks, BridgeBio Oncology Therapeutics has traded between $7.00 and $14.87.

How much debt does BridgeBio Oncology Therapeutics have?

As of the most recent reporting period, BridgeBio Oncology Therapeutics reported total debt of $2.51M.

How much cash does BridgeBio Oncology Therapeutics have on hand?

BridgeBio Oncology Therapeutics reported $54.06M in cash and cash equivalents in its most recent financial results.

What is BridgeBio Oncology Therapeutics’s dividend yield?

BridgeBio Oncology Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services